Free equity investment tool of Japanese companies

Financial Indicator Details

Annual

First quarter

Second quarter

Third quarter

Sponsored Link

Related Company

LTT Bio-Pharma

廣貫堂

小野産業

ダイトーケミックス

Nippon Shikizai

日本化学工業

Kawaguchi Chemical Industry

New Japan Chemical

Carna Biosciences

KOEI CHEMICAL

EDIUNET Related Ranking

EDIUNET

EDIUNET Credit Rating

EDIUNET Industry Avg

EDIUNET Prefectures

Yuho! Industry

EDIUNET Rating News

Prev « 2024-04 » Next

Mon	Tue	Wed	Thu	Fri	Sat	Sun
1 -	2 -	3 -	4 -	5 -	6 -	7 -
8 -	9 -	10 -	11 -	12 -	13 -	14 -
15 -	16 -	17 -	18 -	19 -	20 -	21 -
22 -	23 -	24 -	25 -	26 -	27 -	28 -
29 -	30 -

[Update list]

1/28 Retail Trade (CAWACHI:A etc...

1/27 Banks (The Awa Bank:BBB→A)

1/23 Chemicals (Milbon:AA→AAA)

1/21 Glass & Ceramics Products (..

1/21 Machinery (TSUDAKOMA:C)

1/21 Other Services (Netindex.:CC)

1/20 Other Products (Kurogane Kos..

1/20 Wholesale Trade (リーバイ・..

1/20 Other Services (川崎地質:BB→..

1/17 Chemicals (Kawaguchi Chemica..

 RSS

 Company RSS

 Daily RSS

Sponsored Link

Recently Download Chart

Renesas Electronics

PIONEER etc.

NIPPON COKE & ENGINEERING

KIKUSUI ELECTRONICS etc.

KIKUSUI ELECTRONICS etc.

Financial Indicator Details: LTT Bio-Pharma (Annual )

Two or more periods are displayed by each of financial indicator collectively.Two or more companies can be compared and financial indicator data can also be downloaded.

【Analysis Menu】 Outline Statement Rating Indicator Download

Sponsored Link

*Free Download Financial Indicator data

Indicator Summary: LTT Bio-Pharma (Annual )

Consolidated :Indicator Consolidated | Non-Consolidated

Profitability	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Net profit margin (Industry Average)	-1.11% (-0.50%)	45.58% (1.53%)	-428.06% (-1.67%)	-107.97% (3.05%)
C/F margin (Industry Average)	-28.49% (8.51%)	-221.10% (7.04%)	-72.58% (6.35%)	-95.63% (8.25%)
ROA (Industry Average)	-0.91% (1.04%)	3.50% (2.07%)	-47.90% (0.06%)	- (2.71%)
ROE (Industry Average)	-1.11% (0.03%)	3.63% (2.96%)	-50.58% (4.68%)	-8.26% (4.57%)
Growth	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Equity growth (Industry Average)	- (5.01%)	3.77% (2.61%)	-33.79% (-0.40%)	-7.47% (8.16%)
Sales growth (Industry Average)	- (-)	-91.70% (5.36%)	-1.95% (1.07%)	-40.04% (2.24%)
Net profit growth (Industry Average)	- (203.46%)	438.41% (63.25%)	-1,020.71% (3.89%)	84.87% (90.38%)
Operating C/F growth (Industry Average)	- (275.10%)	35.65% (35.09%)	67.81% (-6.09%)	21.00% (138.39%)
Stability	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Capital adequacy (Industry Average)	81.94% (54.51%)	96.26% (55.00%)	94.71% (53.59%)	- (56.30%)
Liquidity ratio (Industry Average)	304.98% (225.70%)	1,884.05% (237.55%)	2,145.19% (239.89%)	- (236.21%)
C/F ratio current liabilities (Industry Average)	-73.27% (303.31%)	-17.32% (434.79%)	-53.66% (929.73%)	1,365.60% (573.30%)
Quick ratio (Industry Average)	297.53% (148.85%)	1,472.91% (156.17%)	1,998.18% (160.84%)	- (156.81%)
Turnover	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Receivables turnover (Industry Average)	9.08day (94.27day)	79.99day (93.96day)	40.59day (97.92day)	- (98.27day)
Inventory turnover (Industry Average)	- (52.58day)	- (52.64day)	- (56.59day)	- (58.68day)
Payable turnover (Industry Average)	0.16day (49.82day)	3.90day (49.52day)	5.59day (52.10day)	- (51.12day)
Working capita turnover (Industry Average)	8.92day (97.02day)	76.09day (97.08day)	35.00day (102.41day)	- (105.83day)
Stock etc.	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Market Value growth (Industry Average)	- (34.57%)	281.57% (1.49%)	-70.41% (-3.85%)	- (21.16%)
Dividend Yield (Industry Average)	- (1.93%)	- (2.17%)	- (2.45%)	- (2.07%)
PER (Industry Average)	-87.47% (23.06%)	98.62% (16.22%)	-3.16% (29.19%)	- (16.58%)
PBR (Industry Average)	0.97% (1.06%)	3.58% (1.04%)	1.60% (0.95%)	- (1.08%)
PCFR (Industry Average)	-3.42% (9.23%)	-20.33% (-2.43%)	-18.69% (9.50%)	- (7.56%)
PSR (Industry Average)	0.97% (0.88%)	44.95% (1.10%)	13.56% (0.90%)	- (1.01%)

Non-Consolidated :Indicator Consolidated | Non-Consolidated

Profitability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Net profit margin (Industry Average)	200.10% (-27.66%)	144.33% (-4.34%)	-1,183.26% (-5.37%)	-108.41% (-10.69%)	172.09% (8.92%)
C/F margin (Industry Average)	- (0.87%)	- (1.04%)	- (0.82%)	- (-0.81%)	196.82% (-39.63%)
ROA (Industry Average)	3.20% (0.52%)	6.01% (0.92%)	-52.11% (1.42%)	-8.10% (-0.27%)	12.18% (1.53%)
ROE (Industry Average)	3.91% (-0.84%)	6.23% (-0.46%)	-54.91% (1.81%)	-8.26% (3.42%)	12.59% (2.62%)
Growth	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Equity growth (Industry Average)	- (-)	6.65% (3.64%)	-35.64% (3.03%)	-7.47% (0.04%)	15.01% (3.91%)
Sales growth (Industry Average)	- (-)	135.68% (-3.48%)	-30.87% (6.70%)	52.01% (0.75%)	10.35% (-1.74%)
Net profit growth (Industry Average)	- (-)	69.99% (166.48%)	-666.72% (43.48%)	86.07% (-47.04%)	275.16% (62.14%)
Operating C/F growth (Industry Average)	- (-)	- (89.80%)	- (77.44%)	- (-44.41%)	- (46.89%)
Stability	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Capital adequacy (Industry Average)	81.96% (56.79%)	96.42% (57.65%)	94.89% (57.17%)	98.07% (55.93%)	96.73% (57.57%)
Liquidity ratio (Industry Average)	304.51% (337.22%)	1,859.56% (276.75%)	2,173.53% (266.94%)	9,999.64% (314.47%)	4,022.98% (233.84%)
C/F ratio current liabilities (Industry Average)	- (48.90%)	- (53.10%)	- (31.35%)	- (76.77%)	16.70% (31.87%)
Quick ratio (Industry Average)	291.12% (167.28%)	1,432.41% (183.78%)	2,023.14% (174.83%)	9,682.17% (228.06%)	3,931.21% (169.77%)
Turnover	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Receivables turnover (Industry Average)	231.66day (87.55day)	- (98.39day)	6.79day (95.88day)	- (98.58day)	- (67.18day)
Inventory turnover (Industry Average)	- (50.17day)	- (48.43day)	- (47.43day)	- (50.67day)	- (38.21day)
Payable turnover (Industry Average)	8.18day (45.70day)	4.05day (51.63day)	- (51.13day)	- (53.57day)	- (34.24day)
Working capita turnover (Industry Average)	223.48day (92.02day)	-4.05day (95.19day)	6.79day (92.19day)	- (95.69day)	- (71.15day)
Stock etc.	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Market Value growth (Industry Average)	- (-)	281.57% (34.46%)	-70.41% (3.11%)	- (-3.30%)	- (24.19%)
Dividend Yield (Industry Average)	- (0.15%)	- (0.09%)	- (0.10%)	- (0.16%)	- (0.15%)
PER (Industry Average)	24.91% (34.12%)	55.91% (27.80%)	-2.91% (13.58%)	- (22.26%)	- (26.42%)
PBR (Industry Average)	0.97% (0.97%)	3.48% (1.21%)	1.60% (1.17%)	- (1.08%)	- (1.54%)
PCFR (Industry Average)	- (0.27%)	- (0.62%)	- (0.23%)	- (0.08%)	- (4.97%)
PSR (Industry Average)	49.84% (3.42%)	80.70% (4.34%)	34.54% (3.67%)	- (4.37%)	- (10.14%)

Financial Indicator Details: LTT Bio-Pharma

Consolidated :Indicator Consolidated | Non-Consolidated

Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Profitability
Net profit margin	-1.11%	45.58%	-428.06%	-107.97%
C/F margin	-28.49%	-221.10%	-72.58%	-95.63%
ROA	-0.91%	3.50%	-47.90%	-
ROE	-1.11%	3.63%	-50.58%	-8.26%
Recurring margin	-56.22%	13.16%	-239.86%	-105.78%
EBIT margin	-8.61%	47.65%	-427.18%	-106.41%
EBITDA margin	-7.59%	77.96%	-405.85%	-104.23%
NOPAT margin	-5.17%	28.59%	-256.30%	-63.84%
Sales SG rates	73.89%	54.44%	70.09%	0.33%
Sales SG&A rates	98.07%	524.17%	626.47%	845.44%
Sales R&D expenses rates	43.95%	251.20%	390.42%	575.75%
Sales depreciation rates	1.02%	30.31%	21.32%	2.17%
Capital expenditures net sales ratio	-5.54%	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Growth
Growth rate of cash	-	-24.60%	38.70%	-100.00%
Equity growth	-	3.77%	-33.79%	-7.47%
Total assets growth	-	-11.66%	-32.71%	-100.00%
Sales growth	-	-91.70%	-1.95%	-40.04%
Net profit growth	-	438.41%	-1,020.71%	84.87%
Operating C/F growth	-	35.65%	67.81%	21.00%
Recurring profit growth	-	101.94%	-1,886.71%	73.55%
EBIT growth	-	145.83%	-978.94%	85.06%
EBITDA growth	-	185.07%	-610.38%	84.60%
NOPAT growth	-	145.83%	-978.94%	85.06%
Operating expenses growth	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Stability
Capital adequacy	81.94%	96.26%	94.71%	-
Liquidity ratio	304.98%	1,884.05%	2,145.19%	-
C/F ratio current liabilities	-73.27%	-17.32%	-53.66%	1,365.60%
Quick ratio	297.53%	1,472.91%	1,998.18%	-
Fixed ratio	7.02%	4.17%	0.61%	-
D/E ratio	-	-	-	-
Loan to Value Ratio	-	-	-	-
Business investment C/F ratio	19.47%	-	-	-
Liabilities with interest growth	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Turnover
Cash turnover	217.68day	1,979.42day	2,800.36day	-
Receivables turnover	9.08day	79.99day	40.59day	-
Inventory turnover	-	-	-	-
Fixed assets turnover	25.68day	191.21day	18.86day	-
Total asset turnover	446.09day	4,752.11day	3,261.29day	-
Payable turnover	0.16day	3.90day	5.59day	-
Capital turnover	536.22day	6,466.82day	6,595.81day	593.83day
Equity turnover	365.54day	4,574.80day	3,089.02day	4,766.78day
Working capita turnover	8.92day	76.09day	35.00day	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Balance sheet
Cash etc.	¥ 752 M	¥ 567 M	¥ 786 M	-
Accounts receivable-trade	¥ 31 M	¥ 22 M	¥ 11 M	-
Other Current Assets	¥ 50 M	¥ 187 M	¥ 70 M	-
Current Assets	¥ 803 M	¥ 754 M	¥ 856 M	-
Tangible Assets	¥ 88 M	¥ 54 M	¥ 5 M	-
Intangible Assets	¥ 215 M	¥ 178 M	-	-
Investment etc.	¥ 433 M	¥ 373 M	¥ 54 M	-
Total Assets	¥ 1 B	¥ 1 B	¥ 915 M	-
Current Liabilities	¥ 263 M	¥ 40 M	¥ 39 M	¥ -802 M
Fixed Liabilities	¥ 14 M	¥ 10 M	¥ 8 M	-
Liabilities with interest	-	-	-	-
Net Assets	¥ 1 B	¥ 1 B	¥ 867 M	¥ 802 M
Capital stock	¥ 1 B	¥ 1 B	¥ 1 B	¥ 100 M
Capital surplus etc.	¥ -589 M	¥ -542 M	¥ -984 M	¥ 702 M
Liabilities and net assets	¥ 1 B	¥ 1 B	¥ 915 M	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Income statement
Sales	¥ 1 B	¥ 104 M	¥ 102 M	¥ 61 M
Cost of Sales	¥ 931 M	¥ 56 M	¥ 71 M	¥ 204 K
Gross profit	¥ 329 M	¥ 47 M	¥ 30 M	¥ 61 M
Other income	¥ 925 M	¥ 558 M	¥ 371 M	¥ 393 M
SG&A	¥ 1 B	¥ 548 M	¥ 642 M	¥ 519 M
Other expenses	¥ 32 M	¥ 10 M	¥ 198 M	¥ 1 M
Net income	¥ -14 M	¥ 47 M	¥ -438 M	¥ -66 M
Operating income	¥ -907 M	¥ -500 M	¥ -611 M	¥ -458 M
Ordinary Income	¥ -708 M	¥ 13 M	¥ -245 M	¥ -65 M
EBITDA	¥ -95 M	¥ 81 M	¥ -416 M	¥ -64 M
Income before income taxes	¥ -107 M	¥ 52 M	¥ -437 M	¥ -65 M
Depreciation	¥ 12 M	¥ 31 M	¥ 21 M	¥ 1 M
R&D expenses	¥ 554 M	¥ 262 M	¥ 400 M	¥ 353 M
Income taxes	¥ -93 M	¥ 4 M	¥ 1 M	¥ 1 M
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Cash flow statement
Operating CF	¥ -359 M	¥ -231 M	¥ -74 M	¥ -58 M
Investment CF	¥ 540 M	¥ 151 M	¥ 293 M	¥ 7 M
Financial CF	¥ 55 M	-	-	-
Foreign Exchange Effects	-	-	-	-
Net Change in Cash	¥ 235 M	¥ -80 M	¥ 219 M	¥ -50 M
Free CF	¥ 180 M	¥ -80 M	¥ 219 M	¥ -50 M
Capital expenditures	¥ -69 M	-	-	-
Cash dividends paid	-	-	-	-
Repayment loans	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31
Shareowners' equity
Issuance of new shares	-	-	-	-
Dividends from surplus	-	-	-	-
Net income	¥ -14 M	¥ 47 M	¥ -438 M	¥ -66 M
Purchase of treasury stock	-	-	-	-
Other Change in Stockholders Equity	¥ -513 M	-	-	-
Other Change in Net Assets	¥ -110 M	-	¥ -4 M	¥ 1 M
Net Change in Net Assets	¥ -637 M	¥ 47 M	¥ -442 M	¥ -64 M

Financial Indicator Details: LTT Bio-Pharma

Non-Consolidated :Indicator Consolidated | Non-Consolidated

Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Profitability
Net profit margin	200.10%	144.33%	-1,183.26%	-108.41%	172.09%
C/F margin	-	-	-	-	196.82%
ROA	3.20%	6.01%	-52.11%	-8.10%	12.18%
ROE	3.91%	6.23%	-54.91%	-8.26%	12.59%
Recurring margin	-2,496.95%	85.82%	-530.67%	-106.43%	218.29%
EBIT margin	194.04%	144.82%	-1,186.91%	-108.64%	173.49%
EBITDA margin	194.04%	144.82%	-1,186.91%	-108.64%	175.26%
NOPAT margin	116.42%	86.89%	-712.14%	-65.18%	104.09%
Sales SG rates	2.49%	27.94%	25.33%	-	-
Sales SG&A rates	4,006.74%	883.34%	1,528.09%	847.17%	830.23%
Sales R&D expenses rates	2,242.36%	450.91%	993.98%	578.10%	467.19%
Sales depreciation rates	-	-	-	-	1.77%
Capital expenditures net sales ratio	-	-	-	-	-1.20%
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Growth
Growth rate of cash	-	-25.19%	37.47%	-4.67%	18.72%
Equity growth	-	6.65%	-35.64%	-7.47%	15.01%
Total assets growth	-	-9.34%	-34.60%	-10.47%	16.60%
Sales growth	-	135.68%	-30.87%	52.01%	10.35%
Net profit growth	-	69.99%	-666.72%	86.07%	275.16%
Operating C/F growth	-	-	-	-	-
Recurring profit growth	-	108.10%	-527.42%	69.50%	326.32%
EBIT growth	-	75.89%	-666.53%	86.08%	276.23%
EBITDA growth	-	75.89%	-666.53%	86.08%	278.02%
NOPAT growth	-	75.89%	-666.53%	86.08%	276.23%
Operating expenses growth	-	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Stability
Capital adequacy	81.96%	96.42%	94.89%	98.07%	96.73%
Liquidity ratio	304.51%	1,859.56%	2,173.53%	9,999.64%	4,022.98%
C/F ratio current liabilities	-	-	-	-	16.70%
Quick ratio	291.12%	1,432.41%	2,023.14%	9,682.17%	3,931.21%
Fixed ratio	3.28%	0.54%	0.61%	0.49%	0.38%
D/E ratio	-	-	-	-	-
Loan to Value Ratio	-	-	-	-	-
Business investment C/F ratio	-	-	-	-	-0.61%
Liabilities with interest growth	-	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Turnover
Cash turnover	11,082.26day	3,517.52day	6,995.15day	4,386.39day	4,719.18day
Receivables turnover	231.66day	-	6.79day	-	-
Inventory turnover	-	-	-	-	-
Fixed assets turnover	612.47day	46.41day	48.03day	23.60day	19.33day
Total asset turnover	22,775.72day	8,760.45day	8,286.96day	4,880.10day	5,156.73day
Payable turnover	8.18day	4.05day	-	-	-
Capital turnover	27,358.13day	11,607.90day	16,792.08day	596.25day	540.32day
Equity turnover	18,668.09day	8,447.57day	7,864.25day	4,786.25day	4,988.50day
Working capita turnover	223.48day	-4.05day	6.79day	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Balance sheet
Cash etc.	¥ 750 M	¥ 561 M	¥ 771 M	¥ 735 M	¥ 873 M
Accounts receivable-trade	¥ 15 M	-	¥ 750 K	-	-
Other Current Assets	¥ 50 M	¥ 167 M	¥ 58 M	¥ 24 M	¥ 20 M
Current Assets	¥ 801 M	¥ 728 M	¥ 829 M	¥ 759 M	¥ 893 M
Tangible Assets	¥ 41 M	¥ 7 M	¥ 5 M	¥ 3 M	¥ 3 M
Intangible Assets	¥ 215 M	¥ 178 M	-	-	-
Investment etc.	¥ 483 M	¥ 483 M	¥ 79 M	¥ 54 M	¥ 57 M
Total Assets	¥ 1 B	¥ 1 B	¥ 914 M	¥ 818 M	¥ 954 M
Current Liabilities	¥ 263 M	¥ 39 M	¥ 38 M	¥ 7 M	¥ 22 M
Fixed Liabilities	¥ 14 M	¥ 10 M	¥ 8 M	¥ 8 M	¥ 8 M
Liabilities with interest	-	-	-	-	-
Net Assets	¥ 1 B	¥ 1 B	¥ 867 M	¥ 802 M	¥ 923 M
Capital stock	¥ 1 B	¥ 1 B	¥ 1 B	¥ 100 M	¥ 100 M
Capital surplus etc.	¥ -588 M	¥ -504 M	¥ -984 M	¥ 702 M	¥ 823 M
Liabilities and net assets	¥ 1 B	¥ 1 B	¥ 914 M	¥ 818 M	¥ 954 M
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Income statement
Sales	¥ 24 M	¥ 58 M	¥ 40 M	¥ 61 M	¥ 67 M
Cost of Sales	¥ 616 K	¥ 16 M	¥ 10 M	-	-
Gross profit	¥ 24 M	¥ 41 M	¥ 30 M	¥ 61 M	¥ 67 M
Other income	¥ 1 B	¥ 566 M	¥ 377 M	¥ 392 M	¥ 840 M
SG&A	¥ 990 M	¥ 514 M	¥ 615 M	¥ 518 M	¥ 560 M
Other expenses	¥ 33 M	¥ 9 M	¥ 268 M	¥ 1 M	¥ 231 M
Net income	¥ 49 M	¥ 84 M	¥ -476 M	¥ -66 M	¥ 116 M
Operating income	¥ -966 M	¥ -472 M	¥ -585 M	¥ -457 M	¥ -493 M
Ordinary Income	¥ -617 M	¥ 49 M	¥ -213 M	¥ -65 M	¥ 147 M
EBITDA	¥ 47 M	¥ 84 M	¥ -477 M	¥ -66 M	¥ 118 M
Income before income taxes	¥ 50 M	¥ 88 M	¥ -475 M	¥ -65 M	¥ 117 M
Depreciation	-	-	-	-	¥ 1 M
R&D expenses	¥ 554 M	¥ 262 M	¥ 400 M	¥ 353 M	¥ 315 M
Income taxes	¥ 1 M	¥ 4 M	¥ 1 M	¥ 1 M	¥ 1 M
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Cash flow statement
Operating CF	-	-	-	-	¥ 132 M
Investment CF	-	-	-	-	¥ 4 M
Financial CF	-	-	-	-	-
Foreign Exchange Effects	-	-	-	-	-
Net Change in Cash	-	-	-	-	¥ 137 M
Free CF	-	-	-	-	¥ 137 M
Capital expenditures	-	-	-	-	¥ -815 K
Cash dividends paid	-	-	-	-	-
Repayment loans	-	-	-	-	-
Indicator	2009-03-31	2010-03-31	2011-03-31	2012-03-31	2013-03-31
Shareowners' equity
Issuance of new shares	-	-	-	-	-
Dividends from surplus	-	-	-	-	-
Net income	¥ 49 M	¥ 84 M	¥ -476 M	¥ -66 M	¥ 116 M
Purchase of treasury stock	-	-	-	-	-
Other Change in Stockholders Equity	-	-	-	¥ 1 K	¥ 1 K
Other Change in Net Assets	-	-	¥ -4 M	¥ 1 M	¥ 4 M
Net Change in Net Assets	¥ 49 M	¥ 84 M	¥ -480 M	¥ -64 M	¥ 120 M

Free Download

*Free Download Financial Indicator dataMember limited service.

[Data] Net Profit Margin, Sales Growth, Equity Margin etc., 100 or more kinds of financial indicators. (*Consolidated or Non-Consolidated. two or more terms)

Sponsored Link

Related Information: LTT Bio-Pharma (Annual )

Statement Type

Annual : LTT Bio-Pharma

Second quarter : LTT Bio-Pharma

Third quarter : LTT Bio-Pharma

Analysis Menu

Outline : LTT Bio-Pharma

Statement : LTT Bio-Pharma

Rating : LTT Bio-Pharma

Indicator : LTT Bio-Pharma

Download : LTT Bio-Pharma

Industry Comparison Ranking

Chemicals - EDIUNET Industry Rankings

Chemicals - EDIUNET Credit Rating

Chemicals - EDIUNET Industry Avg

Comparison with a neighboring company

Tokyo - EDIUNET Prefectures

Tokyo港区 - EDIUNET Prefectures

Related company's newest statement

Date	Company	Credit Rating	Date
1/23	Milbon	AA→AAA	2013-12-20
1/17	Kawaguchi Chemical Indu..	BBB→BB	2013-11-30
1/17	SANKEI CHEMICAL	A	2013-11-30
1/15	HOKKO CHEMICAL INDUSTRY	BB→B	2013-11-30
1/15	Daito Pharmaceutical Co .	AA	2013-11-30 (Q2)
1/15	KAWAKAMI PAINT MFG.	B→BB	2013-11-30
1/15	旭化学工業	AA	2013-11-30 (Q1)
1/10	OSAKA ORGANIC CHEMICAL ..	BB→BBB	2013-11-30
1/10	HISAMITSU PHARMACEUTICAL	A	2013-11-30 (Q3)
1/10	AMS Life Science	BBB→BB	2013-11-30 (Q1)

EDIUNET Investment News (Chemicals)

1/23 Chemicals (Milbon:AA→AAA)

1/17 Chemicals (Kawaguchi Chemica..

1/15 Chemicals (HOKKO CHEMICAL IN..

1/10 Chemicals (OSAKA ORGANIC CHE..

1/9 Chemicals (SANKO GOSEI:A)

12/27 Chemicals (Niitaka:A)

12/18 Chemicals (KUMIAI CHEMICAL I..

12/12 Chemicals (IHARA CHEMICAL IN..

12/11 Chemicals (Konoshima Chemica..

12/10 Chemicals (NATOCO:AA)

Company Information

Ticker	Market	Industry	Month	report	Rating
LTT Bio-Pharma	4566	TSE Mothers	Chemicals	3	Annual	C

Related Company

New Japan Chemical (Sales ¥ 28 B)

廣貫堂 (Sales ¥ 13 B)

Nippon Shikizai (Sales ¥ 7 B)

小野産業 (Sales ¥ 3 B)

Carna Biosciences (Sales ¥ 510 M)

LTT Bio-Pharma (Sales ¥ 61 M)

Kawaguchi Chemical Industry (Sales ¥ 6 B)

KOEI CHEMICAL (Sales ¥ 18 B)

ダイトーケミックス (Sales ¥ 8 B)

日本化学工業 (Sales ¥ 32 B)

関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .